Adverts

Open Access Articles- Top Results for Morphine-3-glucuronide

Morphine-3-glucuronide

Morphine-3-glucuronide
250px
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Identifiers#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-



20290-09-9 7pxN
ChEMBL ChEMBL1329 7pxY
ChemSpider 4588593 7pxY
Jmol-3D images Image
MeSH Morphine-3-glucuronide
PubChem Template:Chembox PubChem/format
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Properties

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

C23H27NO9
Molar mass 461.462 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 14pxN verify (what is10pxY/10pxN?)
Infobox references

Morphine-3-glucuronide is a metabolite of morphine produced by UGT2B7.[citation needed] It is not active as an opioid agonist,[1] but does have some action as a convulsant, which does not appear to be mediated through opioid receptors,[2] but rather through interaction with glycine and/or GABA receptors. As a polar compound, it has a limited ability to cross the blood–brain barrier, but renal failure may lead to its accumulation and result in seizures. Probenecid and inhibitors of P-glycoprotein can enhance uptake of morphine-3-glucuronide and, to a lesser extent, morphine-6-glucuronide.[3] Reported side effects related to the accumulation of this metabolite include convulsions, agitation, hallucinations, hyperalgesia, and coma.

See also

References

  1. ^ Vindenes V, Ripel A, Handal M, Boix F, Mørland J (July 2009). "Interactions between morphine and the morphine-glucuronides measured by conditioned place preference and locomotor activity". Pharmacology, Biochemistry, and Behavior 93 (1): 1–9. PMID 19351545. doi:10.1016/j.pbb.2009.03.013. 
  2. ^ Hemstapat K, Le L, Edwards SR, Smith MT (July 2009). "Comparative studies of the neuro-excitatory behavioural effects of morphine-3-glucuronide and dynorphin a(2-17) following spinal and supraspinal routes of administration". Pharmacology, Biochemistry, and Behavior 93 (4): 498–505. PMID 19580825. doi:10.1016/j.pbb.2009.06.016. 
  3. ^ Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor. Basic & Clinical Pharmacology (11th ed.). 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.